Abcellera Biologics IncNASDAQ:ABCL
- LAST PRICE3.9000
- TODAY'S CHANGE (%)-0.0200 (-0.5102%)
- Bid / Lots3.9000/ 10
- Ask / Lots3.9100/ 30
- Open / Previous Close3.9500 / 3.9200
- Day Range
- 52 Week Range
- Volume403,704
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABCL |
|---|---|---|
| 09:32 ET | 63295 | 3.9024 |
| 09:34 ET | 1000 | 3.9154 |
| 09:36 ET | 562 | 3.89 |
| 09:38 ET | 1100 | 3.88 |
| 09:39 ET | 7252 | 3.89 |
| 09:41 ET | 1359 | 3.8852 |
| 09:43 ET | 2749 | 3.9 |
| 09:45 ET | 1550 | 3.88 |
| 09:48 ET | 8126 | 3.895 |
| 09:50 ET | 7731 | 3.91 |
| 09:52 ET | 703 | 3.915 |
| 09:54 ET | 2498 | 3.925 |
| 09:56 ET | 5954 | 3.93 |
| 09:57 ET | 2855 | 3.94 |
| 09:59 ET | 6342 | 3.94 |
| 10:01 ET | 4470 | 3.95 |
| 10:03 ET | 1429 | 3.935 |
| 10:06 ET | 18660 | 3.925 |
| 10:08 ET | 1218 | 3.93 |
| 10:10 ET | 1855 | 3.935 |
| 10:12 ET | 1795 | 3.94 |
| 10:14 ET | 1112 | 3.95 |
| 10:15 ET | 3056 | 3.955 |
| 10:17 ET | 1437 | 3.9463 |
| 10:19 ET | 2167 | 3.95 |
| 10:21 ET | 200 | 3.945 |
| 10:24 ET | 2009 | 3.9497 |
| 10:26 ET | 2200 | 3.945 |
| 10:28 ET | 1000 | 3.945 |
| 10:30 ET | 400 | 3.95 |
| 10:32 ET | 2438 | 3.95 |
| 10:33 ET | 7677 | 3.9363 |
| 10:35 ET | 3387 | 3.95 |
| 10:37 ET | 981 | 3.95 |
| 10:39 ET | 3506 | 3.95 |
| 10:42 ET | 2520 | 3.945 |
| 10:44 ET | 1850 | 3.9599 |
| 10:46 ET | 11400 | 3.95 |
| 10:48 ET | 14896 | 3.94 |
| 10:50 ET | 7117 | 3.95 |
| 10:51 ET | 330 | 3.945 |
| 10:53 ET | 1500 | 3.94 |
| 10:55 ET | 2219 | 3.95 |
| 11:00 ET | 900 | 3.955 |
| 11:02 ET | 857 | 3.95 |
| 11:04 ET | 725 | 3.945 |
| 11:06 ET | 1226 | 3.9475 |
| 11:08 ET | 13490 | 3.945 |
| 11:09 ET | 300 | 3.94 |
| 11:11 ET | 14425 | 3.96 |
| 11:13 ET | 1540 | 3.9488 |
| 11:15 ET | 1400 | 3.945 |
| 11:18 ET | 100 | 3.94 |
| 11:20 ET | 4800 | 3.945 |
| 11:22 ET | 1700 | 3.95 |
| 11:24 ET | 559 | 3.9498 |
| 11:26 ET | 3200 | 3.95 |
| 11:27 ET | 100 | 3.945 |
| 11:29 ET | 2232 | 3.9356 |
| 11:31 ET | 100 | 3.925 |
| 11:33 ET | 2000 | 3.9291 |
| 11:36 ET | 300 | 3.93 |
| 11:38 ET | 800 | 3.93 |
| 11:40 ET | 4236 | 3.92 |
| 11:42 ET | 1001 | 3.9199 |
| 11:44 ET | 200 | 3.915 |
| 11:45 ET | 337 | 3.91 |
| 11:47 ET | 100 | 3.9111 |
| 11:49 ET | 1240 | 3.92 |
| 11:51 ET | 508 | 3.9288 |
| 11:54 ET | 201 | 3.925 |
| 11:56 ET | 3740 | 3.94 |
| 12:00 ET | 1487 | 3.93 |
| 12:02 ET | 300 | 3.939 |
| 12:03 ET | 608 | 3.939 |
| 12:05 ET | 500 | 3.94 |
| 12:07 ET | 1641 | 3.93 |
| 12:09 ET | 1465 | 3.925 |
| 12:12 ET | 800 | 3.93 |
| 12:14 ET | 1600 | 3.925 |
| 12:16 ET | 300 | 3.9298 |
| 12:18 ET | 2526 | 3.92 |
| 12:20 ET | 2625 | 3.93 |
| 12:21 ET | 310 | 3.92 |
| 12:23 ET | 6353 | 3.925 |
| 12:25 ET | 648 | 3.93 |
| 12:27 ET | 1900 | 3.925 |
| 12:32 ET | 100 | 3.93 |
| 12:34 ET | 4602 | 3.92 |
| 12:36 ET | 9097 | 3.91 |
| 12:38 ET | 4030 | 3.91 |
| 12:39 ET | 2300 | 3.91 |
| 12:41 ET | 3700 | 3.91 |
| 12:43 ET | 300 | 3.91 |
| 12:45 ET | 250 | 3.9012 |
| 12:48 ET | 150 | 3.9012 |
| 12:50 ET | 1871 | 3.9 |
| 12:52 ET | 200 | 3.9075 |
| 12:54 ET | 1300 | 3.9075 |
| 12:56 ET | 356 | 3.905 |
| 12:57 ET | 200 | 3.905 |
| 12:59 ET | 1430 | 3.9089 |
| 01:01 ET | 4210 | 3.91 |
| 01:03 ET | 100 | 3.9175 |
| 01:06 ET | 2587 | 3.905 |
| 01:08 ET | 560 | 3.905 |
| 01:10 ET | 1250 | 3.905 |
| 01:12 ET | 334 | 3.91 |
| 01:14 ET | 100 | 3.905 |
| 01:15 ET | 870 | 3.9091 |
| 01:17 ET | 100 | 3.905 |
| 01:19 ET | 14462 | 3.9 |
| 01:21 ET | 1388 | 3.905 |
| 01:24 ET | 2000 | 3.905 |
| 01:26 ET | 2146 | 3.9 |
| 01:28 ET | 130 | 3.9 |
Apr 8, 2024
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024, from 12:05PM ET on Monday Apr 08, 2024 by Dow Jones
12:05PM ET on Monday Apr 08, 2024 by Dow Jones
Apr 3, 2024
Press Release: AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024, from 4:07PM ET on Wednesday Apr 03, 2024 by Dow Jones
4:07PM ET on Wednesday Apr 03, 2024 by Dow JonesAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024, from 4:05PM ET on Wednesday Apr 03, 2024 by Dow Jones
4:05PM ET on Wednesday Apr 03, 2024 by Dow Jones
Mar 19, 2024
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024, from 4:05PM ET on Tuesday Mar 19, 2024 by Dow Jones
4:05PM ET on Tuesday Mar 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abcellera Biologics Inc | 1.1B | -7.7x | --- |
Arcutis Biotherapeutics Inc | 1.2B | -2.5x | --- |
Immatics NV | 1.1B | -8.2x | --- |
Silence Therapeutics PLC | 1.0B | -16.4x | --- |
Centessa Pharmaceuticals PLC | 1.1B | -6.7x | --- |
4D Molecular Therapeutics Inc | 1.3B | -9.7x | --- |
Company Information
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Contact Information
- Headquarters
- 2215 Yukon StreetVANCOUVER, BC, Canada V5Y 0A1
- Phone
- 604-559-9005
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Carl Hansen
- Co-Founder, Chief Operating Officer, Director
- Veronique Lecault
- Chief Financial Officer
- Andrew Booth
- Chief Compliance Officer, Corporate Secretary, Chief Legal Officer
- Tryn Stimart
- Chief Commercial Officer
- Neil Aubuchon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $38.0M |
Shares Outstanding | 292.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-0.51 |
Book Value | $3.96 |
P/E Ratio | -7.7x |
Price/Sales (TTM) | 30.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -623.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
